Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leukemia & lymphoma Gaut, D., Oliai, C., Boiarsky, J., Zhang, S., Salhotra, A., Azenkot, T., Kennedy, V. E., Khanna, V., Olmedo Gutierrez, K., Shukla, N., Moskoff, B., Park, G., Afkhami, M., Patel, A., Jeyakumar, D., Mannis, G., Logan, A. C., Jonas, B. A., Schiller, G. 2023: 1-9

Abstract

The rate of MRD clearance in AML with standard consolidation chemotherapy is not well defined. A multi-institution retrospective analysis was performed on 107 consecutively treated AML patients in morphologic complete remission with detectable MRD post-induction therapy who received standard chemotherapy consolidation. In response to standard intermediate/high-dose cytarabine consolidation therapy, 26 of 60 patients (43.3%) with MRD threshold of detection of at least 0.1% converted to MRD-negative status (undetectable with assay used), and 6 of 47 patients (12.8%) with MRD threshold of detection > 0.1% converted to MRD-negative status. Multivariable logistic regression for patients with MRD threshold of detection of at least 0.1% showed that, when controlling for age, ELN risk category, dose of cytarabine, and use of a combination agent, treatment with 1?cycle of consolidation cytarabine versus =2 cycles decreased the odds of conversion of AML to MRD-negative (OR = 0.24, 95% CI 0.07-0.85, p?=?0.03).

View details for DOI 10.1080/10428194.2023.2264426

View details for PubMedID 37801340